Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Liposarcoma

ClinicalTrials.gov lists 187 trials for Liposarcoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 16.

MeSH D008080 Neoplasms Neoplasm C04 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 44 Phase 1/2 Phase 1/2 19 Phase 2 Phase 2 81 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 19 Not applicable Not applicable 7 Observational Observational 12 Expanded access Expanded access 2 Phase 1 Phase 1 44 Phase 1/2 Phase 1/2 19 Phase 2 Phase 2 81 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 19 Not applicable Not applicable 7 Observational Observational 12 Expanded access Expanded access 2

Trials per phase (log scale)

158 of the 187 trials are tagged with Liposarcoma itself; the rest are tagged with a narrower condition beneath it.

Get the Liposarcoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Liposarcoma trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Not applicable
  • Observational

Top of scale: 16

1995: 2 trials (Phase 3 2) 1996: 1 trials (Phase 3 1) 1997: 3 trials (Phase 3 1, Phase 2 1, Phase 1 1) 1998: 3 trials (Phase 3 1, Phase 2 2) 1999: 1 trials (Phase 2 1) 2000: 2 trials (Phase 1/2 1, Phase 1 1) 2001: 2 trials (Phase 2 1, Phase 1 1) 2002: 3 trials (Phase 2 3) 2003: 4 trials (Phase 3 1, Phase 2 3) 2004: 4 trials (Observational 1, Phase 3 1, Phase 2 1, Phase 1 1) 2005: 2 trials (Phase 2 1, Phase 1 1) 2006: 9 trials (Not applicable 1, Phase 3 2, Phase 2 4, Phase 1/2 1, Phase 1 1) 2007: 7 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 4) 2008: 2 trials (Phase 2 1, Phase 1 1) 2009: 2 trials (Not applicable 1, Phase 1/2 1) 2010: 5 trials (Phase 3 1, Phase 2 3, Phase 1/2 1) 2011: 1 trials (Phase 1 1) 2012: 10 trials (Not applicable 1, Phase 3 1, Phase 2 5, Phase 1/2 1, Phase 1 2) 2013: 3 trials (Phase 2 1, Phase 1/2 1, Phase 1 1) 2014: 7 trials (Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2015: 8 trials (Observational 1, Phase 3 1, Phase 2 5, Phase 1 1) 2016: 9 trials (Observational 2, Phase 2/3 1, Phase 2 6) 2017: 8 trials (Observational 1, Phase 2 4, Phase 1/2 1, Phase 1 2) 2018: 8 trials (Phase 2 2, Phase 1/2 1, Phase 1 5) 2019: 8 trials (Phase 3 1, Phase 2 5, Phase 1 2) 2020: 9 trials (Not applicable 2, Phase 2 3, Phase 1 4) 2021: 12 trials (Observational 3, Phase 3 2, Phase 2 2, Phase 1/2 2, Phase 1 3) 2022: 7 trials (Phase 2/3 1, Phase 2 4, Phase 1/2 2) 2023: 5 trials (Phase 3 1, Phase 2 3, Phase 1 1) 2024: 16 trials (Observational 3, Phase 3 1, Phase 2 3, Phase 1/2 2, Phase 1 7) 2025: 13 trials (Not applicable 1, Phase 3 1, Phase 2 3, Phase 1/2 3, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 7
2025 13
2024 16
2023 5
2022 7
2021 12
2020 9
2019 8
2018 8
2017 8

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 9 trials starting in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 33 trials still running at the 2026-10-09 snapshot; registered median of 43 months across 109 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Liposarcoma trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 44
Phase 1/2 19
Phase 2 81
Phase 2/3 3
Phase 3 19
Not applicable 7
Observational 12
Expanded access 2

How many Liposarcoma trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 8
Recruiting 31
Active, not recruiting 17
Available 2
Completed 82

Showing 5 of 8 statuses.

Start your 14-day trial Email me all 8 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Liposarcoma trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 16
European Organisation for Research and Treatment of Cancer - EORTC 15
USWM CT, LLC 4
Adaptimmune 3
Boehringer Ingelheim 3

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Liposarcoma? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 14
Trabectedin 10
PEMBROLIZUMAB 7
Ribociclib 5

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Doxorubicine 25
Ifosfamid 14
Radiation Therapy 13
SQ Fludarabine 7
Pazopanib Pill 6

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Liposarcoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 139 15
Neutrophil count decreased 75 12
Anaemia 60 8
Anemia 60 12
Platelet count decreased 51 12

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Liposarcoma? (52)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study. eLife 2025 Yes
Diagnostic accuracy and safety of percutaneous core needle biopsy of retroperitoneal tumours. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2024 Yes
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Yes
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Yes
Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS. Future oncology (London, England) 2023 Yes

Showing 5 of 52 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (9)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Liposarcoma Annual incidence 1-9 / 1 000 000 United States US Exact
Liposarcoma Annual incidence 1-9 / 1 000 000 United States US Exact
Liposarcoma Annual incidence 1-9 / 1 000 000 United States US Unspecified
Liposarcoma Annual incidence 1-9 / 100 000 Europe Not stated Unspecified
Liposarcoma Point prevalence Unknown Worldwide Not stated Unspecified

Showing 5 of 9 prevalence observations.

Start your 14-day trial Email me all 9 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Liposarcoma 69078 Exact Orphanet Rare Disease Ontology (ORDO)
Liposarcoma 69078 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages